Current treatment regimens for children with Wilms tumors achieve cure rates of approximately 90%. This is the result of advances in basic sciences and especially prospective, randomized, multicenter clinical trials over nearly 50 years. 1 Nevertheless, the question of over-and undertreatment on the cohort level and in individual patients remains important. Treatment protocols of the Children's Oncology Group (COG) in North America and the International Society of Paediatric Oncology (SIOP) in Europe and other countries worldwide strive for a careful balance. 1,2 Despite differences in the initial approaches at diagnosis-primary surgery according to COG and preoperative chemotherapy according to SIOP-treatment after surgery is always followed by risk-adjusted chemotherapy. In both protocols, radiotherapy is limited to advanced stages.The advantage of the COG pathway is the immediate histological verification of tumor subtypes, whereas in the SIOP pathway, surgical risks are reduced, and tumors are downstaged; this results in lower treatment intensity after surgery. According to COG, molecular markers are used for initial risk stratification, whereas according to SIOP, the in vivo response to preoperative chemotherapy can reveal an underlying high-risk blastemal subtype that requires more intensive postoperative treatment. 3 Wilms tumors as embryonal neoplasms display a rather broad range of histological appearances, which together with several clinical characteristics have a strong impact on the disease course. These parameters generally guide the selection of therapeutic regimens. Accordingly, recent clinical trials have been centered on the balance between the intensification of regimens for high-risk cases and further reduction of treatment-possibly to surgery only-for cases with a low risk of subsequent events.Accumulated evidence from successive trials of the National Wilms Tumor Study (NWTS) and COG led to the definition of a very low-risk Wilms tumor (VLRWT) as an entity that requires only surgery to reach an excellent outcome. 4 This group has been defined as patients up to the age of 2 years with stage I tumors that are less than 550 g in weight and have a favorable histology (favorable-histology Wilms tumor [FHWT]; ie, the absence of diffuse anaplasia). Further expansion of this group could spare chemotherapy for additional patients in COG protocols as long as success rates are not compromised. In particular, the rather good prognosis of epithelial-predominant Wilms tumors provides a hint in this direction. 5 This is where the analysis of Parsons et al 6 begins.A retrospective analysis of the COG AREN03B2 study spanning the period of 2006-2017 yielded a cohort of 177 stage I cases with the epithelial-predominant subtype, which is defined as >66% of cells having epithelial characteristics. This cohort showed an overall very low number of events (only 6) and 100% survival. Among the younger patients aged 0 to 2 years, 55% apparently had been classified as having a VLRWT. They received no chemotherapy, and...